An Exploratory Analysis of the Association Between Catechol-O-Methyltransferase and Response to a Randomized Open-Label Placebo Treatment for Cancer-Related Fatigue

Teri W. Hoenemeyer 1, 2*, Navneet Kaur Baidwan 1, Kathryn Hall 2, Ted J. Kaptchuk 3, Kevin R. Fontaine 4† and Tapan S. Mehta 5§

1 Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States, 2 Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, United States, 3 Program of Placebo Studies and the Therapeutic Encounter, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States, 4 Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States, 5 Department of Health Services Administration, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, United States

Specialty section: This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry

Received: 24 March 2021
Accepted: 28 May 2021
Published: 29 June 2021

Citation: Hoenemeyer TW, Baidwan NK, Hall K, Kaptchuk TJ, Fontaine KR and Mehta TS (2021) An Exploratory Analysis of the Association Between Catechol-O-Methyltransferase and Response to a Randomized Open-Label Placebo Treatment for Cancer-Related Fatigue. Front. Psychiatry 12:684556. doi: 10.3389/fpsyg.2021.684556

INTRODUCTION

Cancer-related fatigue (CrF), the most common and distressing condition reported by cancer patients, has detrimental effects on physical functioning and quality of life with only marginally effective treatments such as exercise, psychoeducational, erythropoiesis-stimulating agents, Dexamethasone, modafinal, anti-depressants or no treatment (1–11). Over the past

Previous studies have identified catechol-O-methyltransferase (COMT), as a key enzyme influencing sympathetic function. Although the COMT SNP rs4680 and rs4818, are well-studied, little is known about their influence on cancer-related fatigue (CrF) and placebo response. In this study, we examined whether genetic variation in COMT at the functional SNP rs4680 and linked rs4818, influenced open-label placebo (OLP) responses found in cancer survivors reporting moderate to severe CrF. We randomized cancer survivors (N = 74) reporting moderate-to-severe CrF to receive OLP or to treatment-as-usual (TAU) and assessed if rs4680 and rs4818 were associated with changes in fatigue severity and fatigue-distressed quality of life. At the end of the initial 21 days, the treatments were crossed over and both groups were re-assessed. Participants with the rs4680 high-activity G-allele (G/G or G/A) or rs4818 C/G genotypes reported significant decreases in fatigue severity and improvements in fatigue-distressed quality of life. The COMT rs4818 findings replicated findings in a similar study of OLP in cancer fatigue.

Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02522988.

Keywords: cancer related fatigue, COMT (rs 4680), placebo effect, non-deceptive placebo, COMT rs4818 polymorphism
20 years, many biological mechanisms of CrF have been proposed including 5-hydroxy tryptophan (5-HT) dysregulation, cytokine dysregulation, vagal afferent activation, hypothalamic–pituitary–adrenal axis dysfunction, circadian rhythm disruption, and alterations in muscle and adenosine triphosphate (ATP) metabolism (12–15). One causal theory suggests that CrF results from increases in brain serotonin uptake levels that reduce somatomotor drive, modifies hypothalamic-pituitary-adrenal (HPA) axis function and reduces the capacity to perform physical activities (16–18). Several physiological functions are driven by serotonin uptake including the production of 5-HT, a neurotransmitter regulator that regulates somatomotor drive. When serotonin dysregulation happens, it causes disruptions in 5-HT and tryptophan production and synthesis (19). Finally, it is hypothesized that alterations in the autonomic nervous system result in elevated levels of norepinephrine that increase sympathetic activity and alter inflammatory factors (20, 21). As such, genetic variations in catechol-O-methyltransferase (COMT), an enzyme that degrades catecholamines (e.g., norepinephrine, epinephrine, dopamine and catechol estrogens), dysregulates sympathetic function and increases fatigue (22). Although genetic variants of COMT single nucleotide polymorphisms (SNP), rs4680 or Val158Met, commonly referred to as the “worrier” (val/A allele) and “warrior” (met/G allele) gene and rs4818, are well-studied and proposed to affect schizophrenia, pain, depression and chronic fatigue, little is known about its effect on CrF, a condition also hypothesized to result from dysregulated sympathetic function (23–28).

In a previously reported randomized controlled clinical trial (RCT) (29) testing the effects of open-label placebos among cancer survivors reporting at least moderate fatigue, we found that, compared to treatment-as-usual, participants who knowingly took 2 placebo pills twice a day for 21 days reported a 29% decrease in fatigue severity and a 39% improvement in fatigue-disrupted quality of life. Here we examine a secondary aim of whether genetic variation in COMT at the functional SNP, rs4680 and rs4818 influenced those same OLP responses.

FIGURE 1 | Consort diagram.
MATERIALS AND METHODS

Between August 2015 – May 2017, we conducted a 21-day, single site, two-parallel arm RCT at the University of Alabama at Birmingham’s Comprehensive Cancer Center to compare the effects of open-label placebo (OLP) treatment to treatment-as-usual (TAU) among cancer survivors reporting moderate-to-severe CrF. It must be noted that, for this study, TAU was defined as no treatment which is typically the acceptable clinical practice for treating CrF due to limited effective treatments (30). Cancer survivors who completed cancer treatment at least 6 months to 10 years prior to enrollment and who reported at least moderate fatigue (i.e., equal to/or >4 on a 0–10 scale) were randomized to OLP (N = 39) or TAU (N = 35). Potential participants who reported taking prescription medications for CrF, including anti-depression medications, were screened out due to potentially high placebo effects for same consistently reported in the literature (31). Additionally, participants who were originally randomized to OLP treatment group in main study were followed for an additional 21 days after discontinuing treatment and those in the original TAU were offered treatment and followed for 21 days. Participants were compensated $75 for their time.

Seventy-four participants were randomized to take 2 placebo pills twice a day during each 21-day assigned period OLP = 39; TAU = 35). (It must be mentioned that one participant was lost to follow-up after the baseline visit and dropped from subsequent analyses including results reported here). All participants understood that the placebo pill only contained microcrystalline cellulose and not active ingredients. The primary outcomes, measured at baseline, mid-point (21 days) and at completion were self-reported changes in two scales validated for CrF fatigue symptom severity. As a secondary outcome, saliva samples were collected from 72 participants (1 dropped from study; one refused to provide sample) participants during the baseline visit using the prepIT•L2P purification kit (DNA Genotek), according to the purification protocol, and sent to the Laboratory for Clinical Biochemistry Research located at the University of Vermont for DNA extraction and genotyping. Genotyping of the COMT SNP rs4680 was carried out by PCR amplification followed by automated DNA sequencing on an ABI Prism 3,130 × 1 Genetic Analyzer (forward primer: GGGGCCCTACTGGCCTACCT, reverse primer: TTTTTCAGGTCTGACAACG)24.

Randomization and Blinding

Before any participant visits, a research specialist, otherwise uninvolved in the study, placed white sheets of paper with 40 “Group 1” (OLP) and 40 “Group 2” (TAU) assignments into 80 opaque envelopes. The envelopes were shuffled and randomly placed by a graduate student in a pre-enrollment allotment of files assigned consecutive numbers. As each qualified of OLP on CrF, we used two reliable and well-validated questionnaires, the Fatigue Symptom Inventory (FSI-14) which measures global fatigue symptom severity (FSS) with lower scores indicative of lower fatigue severity. The Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF30) measures the extent to which fatigue disrupts quality of life (FDQoL) (32, 33). The instrument produces five domain scores: general, physical, emotional, mental health and vigor, as well as a total score. Lower scores are indicative of lower level of fatigue-related disruption of quality of life.

Secondary Outcome: Genotyping

Saliva samples were collected from 72 (one dropped from study; one refused to provide sample) participants during the baseline visit using the prepIT•L2P purification kit (DNA Genotek), according to the purification protocol, and sent to the Laboratory for Clinical Biochemistry Research located at the University of Vermont for DNA extraction and genotyping. Genotyping of the COMT SNP rs4680 was carried out by PCR amplification followed by automated DNA sequencing on an ABI Prism 3,130 × 1 Genetic Analyzer (forward primer: GGGGCCCTACTGGCCTACCT, reverse primer: TTTTTCAGGTCTGACAACG).

Randomization and Blinding

Before any participant visits, a research specialist, otherwise uninvolved in the study, placed white sheets of paper with 40 “Group 1” (OLP) and 40 “Group 2” (TAU) assignments into 80 opaque envelopes. The envelopes were shuffled and randomly placed by a graduate student in a pre-enrollment allotment of files assigned consecutive numbers. As each qualified

| TABLE 1 | Baseline characteristics of the study population by treatment group. |
|----------|-----------------|-----------------|
| Trait               | OLP   | TAU   |
| Age (years)         | 58.5 (11.4) | 56.4 (12.4) |
| Race               |        |       |
| White              | 29 (76.3) | 26 (76.5) |
| Black              | 9 (23.7)  | 8 (23.5)  |
| Gender             |        |       |
| Male               | 11 (29.0) | 12 (35.3) |
| Female             | 27 (71.1) | 22 (64.7) |
| rs4680              |        |       |
| met/met (A/A)       | 4 (10.5)  | 7 (20.6)  |
| met/val (A/G)       | 17 (44.7) | 17 (50.0) |
| val/val (G/G)       | 17 (44.7) | 10 (29.4) |
| rs4818              |        |       |
| C/C                | 11 (29.0) | 19 (55.9) |
| C/G                | 18 (47.4) | 13 (38.2) |
| G/G                | 9 (23.7)  | 2 (5.9)   |
| Total              | 38    | 34    |
participant agreed to enroll in the study, he or she was assigned a consecutively numbered file containing the concealed group assignment. During the first clinic visit, after the participant was consented and received the placebo orientation (see below), the envelope containing the group assignment was then opened by the participant and assignment arm revealed. Until the envelopes were open, the interaction with participants was identical. All assessments were performed by a research assistant blinded to randomized allocation.

**Power Calculation**

Our sample size calculations were based on minimal assumptions. Hence for each outcome, our planned sample size calculations indicated that we would have power of 80% assuming a two-tailed two-sample $t$-test on the outcomes at day 21, Type 1 error rate of 0.05, we would need a sample size of 80 to detect an effect size of 0.64. Techniques such as ANCOVA or two-sample independent $t$-test comparing change scores would be powerful or require less sample size to detect the same effect size depending on the correlation between baseline and follow-up measures.

**Statistical Analysis**

This secondary analysis, we used mixed-effects models and analyzed potential associations between the treatment (OLP vs. TAU groups) and genotype (rs4680 and 4818) interactions and post-randomization FSS and FDQoL scores. We also assessed the potential effects of the interaction between treatment and period on the estimate (i.e., mean difference in the scores). We adjusted these analyses for pre-randomization FSS and FDQoL scores and other predictors, including period and demographic variables. In addition, we assessed the potential effects of the interaction between treatment and period on the estimate (i.e., mean difference in the scores), before adjusting for it as a confounder. For all the models, we accounted for the random effects associated with nesting of study IDs and sequence (i.e., sequence in which the treatment was assigned OLP-TAU or TAU-OLP). Statistical significance was tested at the 0.05 level.

**RESULTS**

At baseline, 39 participants were randomized to OLP and 35 were randomized to TAU (Table 1). (As previously mentioned, one participant dropped after initial assessment/sample collection and one participant refused to provide a saliva sample. Both were excluded from the analyses). Mean age in the OLP group was about 59, and 56 years in the TAU group. Over two-thirds of the study participants in both groups were White and the majority were females. Of those randomized to OLP who completed the study and provided saliva samples (N = 37), 45% had the rs4680 genotype A/G (met/val) or G/G (val/val) as did 50% (A/G) and 29% (G/G) of those randomized to TAU group and provided

**TABLE 2 | Mean differences in the FSS and FdQoL scores in the OLP group with reference to the TAU group within the rs4680 and rs4818 SNPs.**

| Exposure (comparing OLP vs. TAU effect within SNPs) | Effect of treatment on FSS and FdQoL scores among the categories within each SNP |
|-----------------------------------------------|---------------------------------|
|                                               | Fatigue symptom severity (FSS) | Fatigue-disrupted quality of life (FdQoL) |
|                                               | Adjusted: period, pre-treatment scores (Est, 95% CI) | + demographics (Est, 95% CI) | + treatment*period (Est, 95% CI) |
|                                               | Adjusted: period, pre-treatment scores (Est, 95% CI) | + demographics (Est, 95% CI) | + treatment*period (Est, 95% CI) |
| rs4680                                         |                                               |                                               |
| A/A                                            | –9.93 (–26.17, 6.30) | –9.91 (–25.49, 5.66) | –9.91 (–25.54, 5.72) |
| A/G                                            | –10.40* (–19.82, –0.97) | –10.29* (–19.34, –1.25) | –10.30* (–19.38, –1.23) |
| G/G                                            | –10.87* (–21.52, –0.23) | –10.64* (–20.86, –0.43) | –10.67* (–20.92, –0.41) |
| rs4818                                         |                                               |                                               |
| C/C                                            | –8.48 (–18.44, 1.47) | –8.42 (–18.00, 1.15) | –8.42 (–18.52, 0.97) |
| C/G                                            | –13.04* (–22.90, –3.18) | –12.97* (–22.46, –3.49) | –12.97* (–22.10, –7.61) |
| G/G                                            | –9.57 (–26.71, 7.58) | –9.09 (–25.52, 7.33) | –9.12 (–25.61, 7.37) |

*Significant (p < 0.05) Reference: TAU (estimates are for OLP, with reference to TAU within rs4680 genotype). Est: mean difference in scores.

For all the models, we accounted for the random effects associated with nesting of study IDs and sequence (i.e., sequence in which the treatment was assigned OLP-TAU or TAU-OLP). Statistical significance was tested at the 0.05 level.

**RESULTS**

At baseline, 39 participants were randomized to OLP and 35 were randomized to TAU (Table 1). (As previously mentioned, one participant dropped after initial assessment/sample collection and one participant refused to provide a saliva sample. Both were excluded from the analyses). Mean age in the OLP group was about 59, and 56 years in the TAU group. Over two-thirds of the study participants in both groups were White and the majority were females. Of those randomized to OLP who completed the study and provided saliva samples (N = 37), 45% had the rs4680 genotype A/G (met/val) or G/G (val/val) as did 50% (A/G) and 29% (G/G) of those randomized to TAU group and provided

**TABLE 2 | Mean differences in the FSS and FdQoL scores in the OLP group with reference to the TAU group within the rs4680 and rs4818 SNPs.**

| Exposure (comparing OLP vs. TAU effect within SNPs) | Effect of treatment on FSS and FdQoL scores among the categories within each SNP |
|-----------------------------------------------|---------------------------------|
|                                               | Fatigue symptom severity (FSS) | Fatigue-disrupted quality of life (FdQoL) |
|                                               | Adjusted: period, pre-treatment scores (Est, 95% CI) | + demographics (Est, 95% CI) | + treatment*period (Est, 95% CI) |
|                                               | Adjusted: period, pre-treatment scores (Est, 95% CI) | + demographics (Est, 95% CI) | + treatment*period (Est, 95% CI) |
| rs4680                                         |                                               |                                               |
| A/A                                            | –9.93 (–26.17, 6.30) | –9.91 (–25.49, 5.66) | –9.91 (–25.54, 5.72) |
| A/G                                            | –10.40* (–19.82, –0.97) | –10.29* (–19.34, –1.25) | –10.30* (–19.38, –1.23) |
| G/G                                            | –10.87* (–21.52, –0.23) | –10.64* (–20.86, –0.43) | –10.67* (–20.92, –0.41) |
| rs4818                                         |                                               |                                               |
| C/C                                            | –8.48 (–18.44, 1.47) | –8.42 (–18.00, 1.15) | –8.42 (–18.52, 0.97) |
| C/G                                            | –13.04* (–22.90, –3.18) | –12.97* (–22.46, –3.49) | –12.97* (–22.10, –7.61) |
| G/G                                            | –9.57 (–26.71, 7.58) | –9.09 (–25.52, 7.33) | –9.12 (–25.61, 7.37) |

*Significant (p < 0.05) Reference: TAU (estimates are for OLP, with reference to TAU within rs4680 genotype). Est: mean difference in scores.
saliva samples ($N = 34$). For the rs4818 genotype category, 29% had the C/C, 47% had the C/G and 24% had the G/G in the OLP group while 56% had C/C, 38% had C/G and 6% had G/G categories in the TAU group.

We compared the OLP group to the TAU group and provide mean differences in FSS and FDQoL scores across the two SNPs: rs4680 and rs4818. Significant decreases were realized in FSS and FDQoL scores among the A/G (met/val) and G/G (val/val) categories for rs4680 and the C/G category for rs4818 for those randomized to OLP compared to TAU. The greatest decreases found in the FSS and FDQoL scores were among the A/G (rs4680) and C/G (rs4818) categories (Table 2, Figures 2, 3). Note that the treatment and period interaction was not significant.

We found no statistical significance when the mean FSS and FDQoL scores were compared within each category for rs4680 (A/A, A/G, G/G) and rs4818 (C/C, C/G, G/G) (results not shown). For example, for rs4680, the mean difference in the FSS scores in OLP group with reference to TAU within the A/A category was not significantly different from that in the A/G category.

**DISCUSSION**

CrF is a multi-factorial condition that is poorly understood. Relative contributors are hypothesized to include various forms of cancer therapy, and comorbid conditions (e.g., anemia, cachexia, sleep disorders, depression) as well as dysregulation of several physiological and biochemical systems. One mechanism proposed as underlying CrF is the dysregulation of sympathetic and parasympathetic nervous system activity. Specifically, genetic variations in COMT (rs4680 and rs4818) have been proposed as degradants of catecholamines dysregulating sympathetic function which increases fatigue (23, 24, 34).

Participants with at least one G-allele in rs4680 (A/G, G/G) and with the rs4818 C/G genotype experienced approximately 10- and 9-point decrease (respectively) in fatigue severity and improvement in fatigue-distressed quality of life. This suggests that specific SNPs, such as rs4680 and rs4818, may influence CrF. However, fatigue-distressed quality of life, only rs4818 C/G participants experienced significant improvements after taking OLP. This finding is consistent with the only other study to look at the association of COMT variants with OLP effects on reducing fatigue in cancer survivors (35).

In our previous study, we found that those randomized to OLP reported a 29 and 39% respective improvement in FSS and FDQoL compared to TAU (29). The results of this further analysis seem to align with warrior and worrier hypothesis of the genotype and may have connections with the resilience literature. Previous research efforts suggest that those with val/met genotype have increased COMT activity and thus lower levels of catecholamines, typically labeled as “warriors” (a behavioral phenotype indicating less susceptibility to pain and stress). On the other hand, those with met/met (due to their heightened susceptibility to pain and stress), have been labeled as “worriers” (36, 37). It has
been reported that there is an overrepresentation of the CC allele of rs4818 among those with persistent chronic fatigue (20).

An increased occurrence of homozygosity for C allele and wild-type G allele for IL-6-174 (a promoter of reduced plasma levels of IL-6, an inflammatory mediator) has also been reported in fatigued breast cancer survivors while others reported significant cytokine association with CrF among women with breast cancer GG genotypes for TNFα-308 (38, 39). As such, polymorphism in neurotransmitter- and HPA axis-related genes associated with COMT variants may have important roles in the etiologies of CrF as it relates to immune dysregulation of cytokines.

Recent research indicates that variation regulation of energy balance and placebo responses may be due to these same genetic variants. Recent studies have demonstrated that genetic variation in the brain’s neurotransmitter (e.g., endorphin, cannabinoid, dopamine, and opioid) pathways may modify how a person responds to placebos (40, 41). Genetic variations in the catechol-O-methyltransferase (COMT) gene, which contains an exonic SNP (rs4680) that can reduce its enzymatic activity, can influence the brain’s level of the neurotransmitter dopamine and may, thereby, influence the extent of an individual’s placebo response (22, 42). Finally, in addition to CrF and chronic fatigue, other studies indicate that G-allele variance may be predictive of more positive treatment effects or less deleterious effects for mood disorders and pain (43–46).

Implications
The present findings add to this growing body of literature focused on identifying the factors that contribute to symptom susceptibility and burden for cancer survivors. Studies like this exploratory analysis suggest that COMT gene variants may be useful in targeting subpopulations with cancer-related fatigue for treatment and symptom management with OLP. In addition, these findings point out different patterns of association of genetic variants for a commonly experienced cancer symptom.

Limitations
The relatively small sample size restricted our ability to conduct additional analyses comparing each of the categories with the SNPs. Moreover, fatigue is a subjective outcome derived from self-report questionnaires. Next, while case-crossover designs may control for between-person confounders, they may still be within-person confounding that may remain unaccounted for (47, 48).

Another limitation of this study is the relative sensitivity of the HPA system itself. While this study explored hypothesized influences of COMT polymorphisms on fatigue, other HPA and autonomic nervous system pathways may have influenced these results. For instance, elevated endogenous levels of 5-HT are known to counteract fatigue and depression, and are highly sensitive to mood changes and stress. Therefore, it could be argued that CrF is not the ideal symptom for testing placebo effects and genetic polymorphisms due to an array of factors (e.g., physical, emotional factors such disease progression, anxiety, stress, depression), that can fluctuate markedly. Additionally, like pain, CrF is accepted as a self-reported condition. As such, objective measures are not currently available and self-reported CrF is susceptible to reporting bias.

CONCLUSIONS
These data provide further evidence about the potential role of genetic loci in placebo response. Both COMT rs4680 high-activity G-allele and rs4818 C/G genotype were significantly associated with decreased fatigue severity and improved fatigue-distressed quality of life among cancer survivors participating in a trial of the non-deceptive administration of placebo pills. Although additional work is needed to replicate and elaborate on our findings, these data may provide supportive evidence for a role of genetic loci in open-placebo response and the magnitude of differences between the clinically meaningful improvements found in fatigue severity and fatigue-disrupted quality of life across genotypes.

DATA AVAILABILITY STATEMENT
The trial protocol and datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request and with the authorization of the University of Alabama at Birmingham’s Institutional Review Board.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by University of Alabama at Birmingham, Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
KH, TJK, and KRF contributed to expertise on trial design, open label placebo and COMT genetic outcomes. TSM contributed as senior author with supervision on genetic outcomes analyses. All authors contributed to the article and approved the submitted version.

FUNDING
Comprehensive Cancer Center, University of Alabama at Birmingham and the Foundation for the Science of the Therapeutic Encounter, Cambridge, Massachusetts. TJK supported by NIH/NCCIH grants # 2K24 AT004095 and #R01AT008573.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.684556/full#supplementary-material

Hoenemeyer et al. COMT and Response to OLP
REFERENCES

1. American Cancer Society. Cancer Treatment and Survivorship Facts and Figures: 2014-2015. Available online at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042801.pdf (accessed July 31, 2018).
2. Bower JE, Bak K, Berger A, Breitbard W, Escalante CP, Ganz PA, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American society of clinical oncology clinical practice guideline adaptation. J Clin Oncol. (2014) 32:1840-51. doi: 10.1200/JCO.2013.33.4495
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. (2015). Available online at: http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf (accessed July 31, 2018).
4. National Cancer Institute. Fatigue PDQ. Health Professional Version. Available online at: http://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq (accessed July 31, 2018).
5. Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA, Johnson BT. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. (2011) 20:123–33. doi: 10.1158/1055-9965.EPI-10-0988
6. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. (2012) 11:CD006145. doi: 10.1002/14651858.CD006145.pub2
7. Davis JM, Bailey, SP. Possible mechanisms of central nervous system adaptation. J Clin Oncol. (2014) 32:1840–51. doi: 10.1200/JCO.2013.33.4495
8. Hoenemeyer et al. COMT and Response to OLP (2014) 11:CD006953. doi: 10.1002/14651858.CD006953.pub2
9. Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol. (2007) 26:660–7. doi: 10.1037/0278-6133.26.6.660
10. Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull. (2008) 134:700–41. doi: 10.1037/a0012825
11. Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. J Prev Med. (2012) 43:e1–24. doi: 10.1016/j.amepre.2012.04.027
12. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. (2008) 100:1155–66. doi: 10.1093/jnci/djn250
13. Davis JM, Bailey, SP. Possible mechanisms of central nervous system fatigue during exercise. Med Sci Sport Exerc. (1997) 29:45–57. doi: 10.1097/00005768-199701000-00008
14. Castell L, Yamamoto T, Phoenix J, Newsholme EL. The role of tryptophan in fatigue in different conditions of stress. Adv Exp Med Biol. (1999) 467:697–704. doi: 10.1007/978-1-4615-4709-9_90
15. Barsevick A, Frost M, Zwierdenaar A, Hall P, Halyard M, GENEOFL. Consortium. I’m so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res. (2010) 19:1419–27. doi: 10.1007/s11136-010-9757-7
40. Kambur O, Männistö P. Basic aspects of catechol-O-methyltransferase and the clinical applications of its inhibitors. In: International Review of Neurobiology. Amsterdam: Academic press (2010). p. 227–79.
41. Hall KT, Lembo AJ, Kirsch I, Ziegas DC, Douaiher J, Jensen KB, et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. (2012) 7:e48135. doi: 10.1371/journal.pone.0048135
42. Colagiuri B, Schenk LA, Kessler MD, Dorsey SG, Colloca L. The placebo effect: from concepts to genes. Neuroscience. (2015) 307:171–90. doi: 10.1016/j.neuroscience.2015.08.017
43. Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med. (2015) 21:285–94. doi: 10.1016/j.molmed.2015.02.009
44. Wang RS, Hall KT, Giulianini F, Passow D, Kaptchuk TJ, Loscalzo J. Network analysis of the genomic basis of the placebo effect. JCI Insight. (2017) 2:e93911. doi: 10.1172/jci.insight.93911
45. Lin CH, Chaudhuri KR, Fan JY, Ko CI, Rizos A, Chang CW, et al. Depression and catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson’s disease. Sci Rep. (2017) 7:6306. doi: 10.1038/s41598-017-06782-z
46. Fernadez de-Las-Peñas C, Ambite-Quesada S, Palacios-Ceña M, Guillem-Mesado A, Guerrero-Peral Á, Pareja JA, et al. Catechol-O-Methyltransferase (COMT) rs4680 Val158Met polymorphism is associated with widespread pressure pain sensitivity and depression in women with chronic, but not episodic, tension-type headache. Clin J Pain. (2019) 35:345–52. doi: 10.1097/AJP.0000000000000684
47. Liu J, Wu J, Nie G, Zeng W, Zhand M, Tan L, et al. Catechol-O-methyltransferase SNP rs4680 influence risk of mood disorder: a meta-analysis. Int J Clin Exp Med. (2016) 9:6152–65.
48. Lombardi DA. The case-crossover study: a novel design in evaluating transient fatigue as a risk factor for road traffic accidents. Sleep. (2010) 33:283–4. doi: 10.1093/sleep/33.3.283

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hoenemeyer, Baidwan, Hall, Kaptchuk, Fontaine and Mehta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.